Logo image of EKSO

EKSO BIONICS HOLDINGS INC (EKSO) Stock Fundamental Analysis

USA - NASDAQ:EKSO - US2826444000 - Common Stock

4.61 USD
-0.3 (-6.11%)
Last: 10/17/2025, 8:08:06 PM
4.7301 USD
+0.12 (+2.61%)
After Hours: 10/17/2025, 8:08:06 PM
Fundamental Rating

2

Taking everything into account, EKSO scores 2 out of 10 in our fundamental rating. EKSO was compared to 191 industry peers in the Health Care Equipment & Supplies industry. EKSO has a bad profitability rating. Also its financial health evaluation is rather negative. EKSO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EKSO has reported negative net income.
In the past year EKSO has reported a negative cash flow from operations.
In the past 5 years EKSO always reported negative net income.
EKSO had a negative operating cash flow in each of the past 5 years.
EKSO Yearly Net Income VS EBIT VS OCF VS FCFEKSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

EKSO's Return On Assets of -48.82% is on the low side compared to the rest of the industry. EKSO is outperformed by 65.97% of its industry peers.
Looking at the Return On Equity, with a value of -103.49%, EKSO is doing worse than 62.83% of the companies in the same industry.
Industry RankSector Rank
ROA -48.82%
ROE -103.49%
ROIC N/A
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
EKSO Yearly ROA, ROE, ROICEKSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

The Gross Margin of EKSO (51.52%) is comparable to the rest of the industry.
EKSO's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for EKSO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
EKSO Yearly Profit, Operating, Gross MarginsEKSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

EKSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EKSO has been increased compared to 1 year ago.
Compared to 5 years ago, EKSO has more shares outstanding
EKSO has a better debt/assets ratio than last year.
EKSO Yearly Shares OutstandingEKSO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M
EKSO Yearly Total Debt VS Total AssetsEKSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

EKSO has an Altman-Z score of -15.47. This is a bad value and indicates that EKSO is not financially healthy and even has some risk of bankruptcy.
EKSO's Altman-Z score of -15.47 is on the low side compared to the rest of the industry. EKSO is outperformed by 85.86% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that EKSO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.31, EKSO is in line with its industry, outperforming 50.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z -15.47
ROIC/WACCN/A
WACC6.73%
EKSO Yearly LT Debt VS Equity VS FCFEKSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

A Current Ratio of 2.38 indicates that EKSO has no problem at all paying its short term obligations.
EKSO has a Current ratio of 2.38. This is comparable to the rest of the industry: EKSO outperforms 46.60% of its industry peers.
EKSO has a Quick Ratio of 1.57. This is a normal value and indicates that EKSO is financially healthy and should not expect problems in meeting its short term obligations.
EKSO's Quick ratio of 1.57 is in line compared to the rest of the industry. EKSO outperforms 41.88% of its industry peers.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 1.57
EKSO Yearly Current Assets VS Current LiabilitesEKSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

EKSO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.97%, which is quite impressive.
The Revenue for EKSO has decreased by -19.34% in the past year. This is quite bad
Measured over the past years, EKSO shows a small growth in Revenue. The Revenue has been growing by 5.19% on average per year.
EPS 1Y (TTM)43.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.41%
Revenue 1Y (TTM)-19.34%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%-58.44%

3.2 Future

Based on estimates for the next years, EKSO will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.47% on average per year.
EKSO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.01% yearly.
EPS Next Y47.03%
EPS Next 2Y31.23%
EPS Next 3Y20.9%
EPS Next 5Y16.47%
Revenue Next Year-7.06%
Revenue Next 2Y18.06%
Revenue Next 3Y18.01%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
EKSO Yearly Revenue VS EstimatesEKSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M 20M 25M
EKSO Yearly EPS VS EstimatesEKSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -100 -200 -300 -400

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EKSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EKSO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EKSO Price Earnings VS Forward Price EarningsEKSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EKSO Per share dataEKSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

EKSO's earnings are expected to grow with 20.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.23%
EPS Next 3Y20.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EKSO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EKSO BIONICS HOLDINGS INC

NASDAQ:EKSO (10/17/2025, 8:08:06 PM)

After market: 4.7301 +0.12 (+2.61%)

4.61

-0.3 (-6.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)10-27 2025-10-27/amc
Inst Owners2.14%
Inst Owner Change0%
Ins Owners5.93%
Ins Owner Change5.66%
Market Cap12.03M
Analysts82.5
Price Target35.45 (668.98%)
Short Float %4.74%
Short Ratio1.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.5%
Min EPS beat(2)-6.95%
Max EPS beat(2)9.95%
EPS beat(4)2
Avg EPS beat(4)-15.49%
Min EPS beat(4)-71.57%
Max EPS beat(4)9.95%
EPS beat(8)4
Avg EPS beat(8)-19.31%
EPS beat(12)4
Avg EPS beat(12)-17.43%
EPS beat(16)8
Avg EPS beat(16)-8.64%
Revenue beat(2)0
Avg Revenue beat(2)-40.84%
Min Revenue beat(2)-53.24%
Max Revenue beat(2)-28.45%
Revenue beat(4)0
Avg Revenue beat(4)-27.5%
Min Revenue beat(4)-53.24%
Max Revenue beat(4)-1.24%
Revenue beat(8)1
Avg Revenue beat(8)-17.81%
Revenue beat(12)3
Avg Revenue beat(12)-9.38%
Revenue beat(16)5
Avg Revenue beat(16)-4.85%
PT rev (1m)0%
PT rev (3m)-7.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.65%
EPS NY rev (1m)17.78%
EPS NY rev (3m)17.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.82
P/FCF N/A
P/OCF N/A
P/B 1.1
P/tB 1.92
EV/EBITDA N/A
EPS(TTM)-6.64
EYN/A
EPS(NY)-2.38
Fwd EYN/A
FCF(TTM)-3.52
FCFYN/A
OCF(TTM)-3.49
OCFYN/A
SpS5.61
BVpS4.19
TBVpS2.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.82%
ROE -103.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.52%
FCFM N/A
ROA(3y)-43.98%
ROA(5y)-46.15%
ROE(3y)-89.67%
ROE(5y)-131.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.01%
GM growth 5Y1.79%
F-Score2
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.06%
Cap/Sales 0.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 1.57
Altman-Z -15.47
F-Score2
WACC6.73%
ROIC/WACCN/A
Cap/Depr(3y)10.97%
Cap/Depr(5y)8.72%
Cap/Sales(3y)0.85%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.41%
EPS Next Y47.03%
EPS Next 2Y31.23%
EPS Next 3Y20.9%
EPS Next 5Y16.47%
Revenue 1Y (TTM)-19.34%
Revenue growth 3Y16.8%
Revenue growth 5Y5.19%
Sales Q2Q%-58.44%
Revenue Next Year-7.06%
Revenue Next 2Y18.06%
Revenue Next 3Y18.01%
Revenue Next 5YN/A
EBIT growth 1Y-1.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.74%
OCF growth 3YN/A
OCF growth 5YN/A